Resources

The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies. This article was originally published on contagionlive.com.  

This article was originally published in Genetic Engineering & Biotechnology News under the title of The Antimicrobial Resistance Crisis Eradicating a Global Health Threat

Reversing the Rapid Rise of Antibiotic Resistance. Greg Mario joins David E. Williams to discuss the real and potentially imminent dangers of antibiotic-resistant infections and the new technologies being developed to combat this growing threat.

Antimicrobial resistance (AMR) is not a new phenomenon; it has been a persistent challenge since the discovery of antibiotics. TAXIS Pharmaceuticals is at the forefront of addressing antimicrobial resistance, developing innovative antimicrobial solutions.

Startup Revolution: Greg Mario of TAXIS Pharmaceuticals On How Their Emerging Startup is Changing the Game

On July 25, House Budget Committee bipartisan roundtable entitled, “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance (AMR) and the Broken Antibiotic Development Pipeline.”

Antibiotic resistance – or antimicrobial resistance (AMR) – has been making headlines for decades. At TAXIS Pharmaceuticals, we have been working since 2009 on the development of compounds that combat antimicrobial resistance.

TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant to Advance Research and Development of Combination Therapy to Combat Antibiotic-Resistant Pneumonia. Originally published in NORTH BRUNSWICK, N.J., May 1, 2024 /PRNewswire-PRWeb/

FtsZ inhibitors represent a new drug class as no drugs using this mode of action (MOA) have been approved by regulators. In this paper, we present the screening and evaluation of a benzamide class that is functionalized at the alkoxy fragment targeting Gram-negative bacteria.